First Steps Towards a Risk of Bias Corpus of Randomized Controlled Trials

被引:0
作者
Dhrangadhariya, Anjani [1 ,2 ]
Hilfiker, Roger [3 ]
Sattelmayer, Martin [4 ]
Giacomino, Katia [4 ]
Caliesch, Rahel [4 ]
Elsig, Simone [4 ]
Naderi, Nona [5 ,6 ]
Mueller, Henning [1 ,2 ]
机构
[1] HES SO Valais Wallis, Inst Informat, Sierre, Switzerland
[2] Univ Geneva UNIGE, Geneva, Switzerland
[3] Univ Lausanne, IUFRS, Lausanne, Switzerland
[4] HES SO Valais Wallis, Sch Hlth Sci, Leukerbad, Switzerland
[5] HES SO Geneva, Geneva Sch Business Adm, Geneva, Switzerland
[6] SIB Swiss Inst Bioinformat SIB, Geneva, Switzerland
来源
CARING IS SHARING-EXPLOITING THE VALUE IN DATA FOR HEALTH AND INNOVATION-PROCEEDINGS OF MIE 2023 | 2023年 / 302卷
关键词
risk of bias; annotation; systematic reviews; corpus; automation;
D O I
10.3233/SHTI230210
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
Risk of bias (RoB) assessment of randomized clinical trials (RCTs) is vital to conducting systematic reviews. Manual RoB assessment for hundreds of RCTs is a cognitively demanding, lengthy process and is prone to subjective judgment. Supervised machine learning (ML) can help to accelerate this process but requires a hand-labelled corpus. There are currently no RoB annotation guidelines for randomized clinical trials or annotated corpora. In this pilot project, we test the practicality of directly using the revised Cochrane RoB 2.0 guidelines for developing an RoB annotated corpus using a novel multi-level annotation scheme. We report inter-annotator agreement among four annotators who used Cochrane RoB 2.0 guidelines. The agreement ranges between 0% for some bias classes and 76% for others. Finally, we discuss the shortcomings of this direct translation of annotation guidelines and scheme and suggest approaches to improve them to obtain an RoB annotated corpus suitable for ML.
引用
收藏
页码:586 / 590
页数:5
相关论文
共 7 条
[1]  
Deleger L, 2014, AMIA ANN S P, P144
[2]   Randomised controlled trials - the gold standard for effectiveness research Study design: randomised controlled trials [J].
Hariton, Eduardo ;
Locascio, Joseph J. .
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 125 (13) :1716-1716
[3]  
Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]
[4]   Co-infections in people with COVID-19: a systematic review and meta-analysis [J].
Lansbury, Louise ;
Lim, Benjamin ;
Baskaran, Vadsala ;
Lim, Wei Shen .
JOURNAL OF INFECTION, 2020, 81 (02) :266-275
[5]   Automating Risk of Bias Assessment for Clinical Trials [J].
Marshall, Iain J. ;
Kuiper, Joel ;
Wallace, Byron C. .
IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS, 2015, 19 (04) :1406-1412
[6]   Machine learning to assist risk-of-bias assessments in systematic reviews [J].
Millard, Louise A. C. ;
Flach, Peter A. ;
Higgins, Julian P. T. .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2016, 45 (01) :266-277
[7]   Risk of bias assessment in preclinical literature using natural language processing [J].
Wang, Qianying ;
Liao, Jing ;
Lapata, Mirella ;
Macleod, Malcolm .
RESEARCH SYNTHESIS METHODS, 2022, 13 (03) :368-380